Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)
NCT ID: NCT01379209
Last Updated: 2019-10-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
68 participants
INTERVENTIONAL
2011-09-30
2017-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The study will be separated into two parts; a dose escalation phase to assess safety, followed by a large expansion phase to further evaluate the pharmacologic effects of either a Maximum Tolerated Dose, Maximum Feasible Dose or optimal pharmacologically active dose of RGI-2001. The initial dose escalation safety portion of the study (Part 1) will include higher risk patients and limit the unrelated donor transplants. After safety is established in part 1 of the study, the second portion of the study will expand the enrollment criteria and allow transplantation by either related or unrelated donors.
This study will endeavor to identify the dose range at which RGI-2001 has an acceptable safety profile, at which biologic activity is observed, and to guide possible dose levels to utilize in later phase studies based on biological activity.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
RGI-2001 for the Prevention of Acute Graft-vs-Host Disease in Subjects Following Allogeneic Hematopoietic Stem Cell Transplantation
NCT04014790
Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD
NCT00186628
Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT
NCT01220297
Calcineurin Inhibitor-Free Interventions BMT CTN 1301 for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
NCT02345850
Haplo Peripheral Blood Sct In GVHD Prevention
NCT04473911
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In Part 1 (Phase 1: Dose Escalation Phase), patients will receive a single intravenous administration of RGI-2001 approximately 30 minutes after completion of the transplant (either allogeneic PBSCs or allogenic bone marrow transplantation (unmodified)) with the dosage based upon the assigned treatment cohort. Eligible patients will be enrolled in five to seven centers in the United States. Patients who are undergoing AHSCT will be enrolled in a sequential group dose-escalating fashion to determine the safety, tolerability, pharmacokinetic profile, and the MTD or MFD of RGI-2001. It is anticipated that up to six dose levels will be evaluated in Part 1, with an option for an additional cohort (Cohort 7) if the MTD is not reached and pharmacodynamic markers suggest higher doses are warranted.
In Part 2 (Expansion Phase), one or more doses below the MTD or MFD will be selected based on a potential correlation between GvHD and biological activity to further assess safety and biologic activity. Approximately 30 patients who are undergoing either allogeneic PBSCs or allogenic bone marrow transplantation (unmodified) will be enrolled in Part 2 of the study.
Patients will be monitored for safety for 29 days after the transplant procedure.
All patients will be followed for 100 days following transplant procedure for the incidence of acute GvHD, according to the Modified Keystone Criteria for grading acute GvHD (Przepiorka D, et al)
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
RGI-2001 0.001 μg/kg + Standard of Care GVHD Prophylaxis
RGI-2001 will be add to standard treatment with a calcineurin inhibitor, in combination with either methotrexate, mycophenolate mofetil, or sirolimus all at doses as per the institutional protocols
Dose escalation cohort 1 in part 1 of this study will include 2-6 patients
RGI-2001
A single administration of RGI-2001 on Day 0 post AHSCT.
Calcineurin Inhibitors
GVHD prophylaxis according to institutional guidelines. Subjects could have received any number/combinations of treatments.
Allogeneic Hematopoietic Stem Cell Transplantation
According to institutional guidelines.
Conditioning Regimen
Myeloablative preparative treatment according to institutional guidelines. Subjects could have received any number/combinations of treatments.
Allogeneic Bone Marrow Transplantation
According to institutional guidelines
Methotrexate
Mofetil Mycophenolate
sirolimus
Administered for GVHD prophylaxis as per institutional guidelines
RGI-2001 0.01 μg/kg + Standard of Care GVHD Prophylaxis
RGI-2001 will be add to standard treatment with a calcineurin inhibitor, in combination with either methotrexate, mycophenolate mofetil, or sirolimus all at doses as per the institutional protocols
Cohort 2 in part 1 of this study will include 2-6 patients
RGI-2001
A single administration of RGI-2001 on Day 0 post AHSCT.
Calcineurin Inhibitors
GVHD prophylaxis according to institutional guidelines. Subjects could have received any number/combinations of treatments.
Allogeneic Hematopoietic Stem Cell Transplantation
According to institutional guidelines.
Conditioning Regimen
Myeloablative preparative treatment according to institutional guidelines. Subjects could have received any number/combinations of treatments.
Allogeneic Bone Marrow Transplantation
According to institutional guidelines
Methotrexate
Mofetil Mycophenolate
sirolimus
Administered for GVHD prophylaxis as per institutional guidelines
RGI-2001 0.1 μg/kg + Standard of Care GVHD Prophylaxis
RGI-2001 will be add to standard treatment with a calcineurin inhibitor, in combination with either methotrexate, mycophenolate mofetil, or sirolimus all at doses as per the institutional protocols
Cohort 3 in part 1 of this study will include 2-6 patients
RGI-2001
A single administration of RGI-2001 on Day 0 post AHSCT.
Calcineurin Inhibitors
GVHD prophylaxis according to institutional guidelines. Subjects could have received any number/combinations of treatments.
Allogeneic Hematopoietic Stem Cell Transplantation
According to institutional guidelines.
Conditioning Regimen
Myeloablative preparative treatment according to institutional guidelines. Subjects could have received any number/combinations of treatments.
Allogeneic Bone Marrow Transplantation
According to institutional guidelines
Methotrexate
Mofetil Mycophenolate
sirolimus
Administered for GVHD prophylaxis as per institutional guidelines
RGI-2001 1.0 μg/kg + Standard of Care GVHD Prophylaxis
RGI-2001 will be add to standard treatment with a calcineurin inhibitor, in combination with either methotrexate, mycophenolate mofetil, or sirolimus all at doses as per the institutional protocols
Cohort 4 in part 1 of this study will include 2-6 patients
RGI-2001
A single administration of RGI-2001 on Day 0 post AHSCT.
Calcineurin Inhibitors
GVHD prophylaxis according to institutional guidelines. Subjects could have received any number/combinations of treatments.
Allogeneic Hematopoietic Stem Cell Transplantation
According to institutional guidelines.
Conditioning Regimen
Myeloablative preparative treatment according to institutional guidelines. Subjects could have received any number/combinations of treatments.
Allogeneic Bone Marrow Transplantation
According to institutional guidelines
Methotrexate
Mofetil Mycophenolate
sirolimus
Administered for GVHD prophylaxis as per institutional guidelines
RGI-2001 10 μg/kg + Standard of Care GVHD Prophylaxis
RGI-2001 will be add to standard treatment with a calcineurin inhibitor, in combination with either methotrexate, mycophenolate mofetil, or sirolimus all at doses as per the institutional protocols
Cohort 5 in part 1 of this study will include 2-6 patients
RGI-2001
A single administration of RGI-2001 on Day 0 post AHSCT.
Calcineurin Inhibitors
GVHD prophylaxis according to institutional guidelines. Subjects could have received any number/combinations of treatments.
Allogeneic Hematopoietic Stem Cell Transplantation
According to institutional guidelines.
Conditioning Regimen
Myeloablative preparative treatment according to institutional guidelines. Subjects could have received any number/combinations of treatments.
Allogeneic Bone Marrow Transplantation
According to institutional guidelines
Methotrexate
Mofetil Mycophenolate
sirolimus
Administered for GVHD prophylaxis as per institutional guidelines
RGI-2001 100 μg/kg + Standard of Care GVHD Prophylaxis
RGI-2001 will be add to standard treatment with a calcineurin inhibitor, in combination with either methotrexate, mycophenolate mofetil, or sirolimus all at doses as per the institutional protocols
Cohort 6 in part 1 of this study will include 2-6 patients
RGI-2001
A single administration of RGI-2001 on Day 0 post AHSCT.
Calcineurin Inhibitors
GVHD prophylaxis according to institutional guidelines. Subjects could have received any number/combinations of treatments.
Allogeneic Hematopoietic Stem Cell Transplantation
According to institutional guidelines.
Conditioning Regimen
Myeloablative preparative treatment according to institutional guidelines. Subjects could have received any number/combinations of treatments.
Allogeneic Bone Marrow Transplantation
According to institutional guidelines
Methotrexate
Mofetil Mycophenolate
sirolimus
Administered for GVHD prophylaxis as per institutional guidelines
RGI-2001 250μg/kg + Standard of Care GVHD Prophylaxis
RGI-2001 will be add to standard treatment with a calcineurin inhibitor, in combination with either methotrexate, mycophenolate mofetil, or sirolimus all at doses as per the institutional protocols
Cohort 7 in part 1 of this study will include 2-6 patients (optional)
RGI-2001
A single administration of RGI-2001 on Day 0 post AHSCT.
Calcineurin Inhibitors
GVHD prophylaxis according to institutional guidelines. Subjects could have received any number/combinations of treatments.
Allogeneic Hematopoietic Stem Cell Transplantation
According to institutional guidelines.
Conditioning Regimen
Myeloablative preparative treatment according to institutional guidelines. Subjects could have received any number/combinations of treatments.
Allogeneic Bone Marrow Transplantation
According to institutional guidelines
Methotrexate
Mofetil Mycophenolate
sirolimus
Administered for GVHD prophylaxis as per institutional guidelines
RGI-2001 + Standard of Care GVHD Prophylaxis
RGI-2001 will be add to standard treatment with a calcineurin inhibitor, in combination with either methotrexate, mycophenolate mofetil, or sirolimus all at doses as per the institutional protocols
In part 2 of this study the best dose or doses determined from part 1 will be administered in up to 30 persons.
RGI-2001
A single administration of RGI-2001 on Day 0 post AHSCT.
Calcineurin Inhibitors
GVHD prophylaxis according to institutional guidelines. Subjects could have received any number/combinations of treatments.
Allogeneic Hematopoietic Stem Cell Transplantation
According to institutional guidelines.
Conditioning Regimen
Myeloablative preparative treatment according to institutional guidelines. Subjects could have received any number/combinations of treatments.
Allogeneic Bone Marrow Transplantation
According to institutional guidelines
Methotrexate
Mofetil Mycophenolate
sirolimus
Administered for GVHD prophylaxis as per institutional guidelines
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
RGI-2001
A single administration of RGI-2001 on Day 0 post AHSCT.
Calcineurin Inhibitors
GVHD prophylaxis according to institutional guidelines. Subjects could have received any number/combinations of treatments.
Allogeneic Hematopoietic Stem Cell Transplantation
According to institutional guidelines.
Conditioning Regimen
Myeloablative preparative treatment according to institutional guidelines. Subjects could have received any number/combinations of treatments.
Allogeneic Bone Marrow Transplantation
According to institutional guidelines
Methotrexate
Mofetil Mycophenolate
sirolimus
Administered for GVHD prophylaxis as per institutional guidelines
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Meet one of the following underlying disease criteria:
a. Acute myelogenous leukemia (AML) i. First or subsequent morphologic remission b. Acute lymphoblastic leukemia (ALL) i. First or subsequent morphologic remission c. Chronic myelogenous leukemia (CML) i. Chronic phase; or ii. Accelerated phase d. Multiple Myeloma (MM) i. Not more than 20% plasma cells in the bone marrow e. Myelodysplastic syndrome (MDS), including chronic myelomonocytic leukemia (CMML), who have received at least one previous induction regimen and have \<10% blasts f. Myeloproliferative disorder (MPD), including; i. myeloid metaplasia, and ii. myelofibrosis g. Non-Hodgkin's Lymphoma (NHL) i. High-risk NHL in first remission; or ii. Relapsed or refractory NHL h. Hodgkin's lymphoma (HL) beyond first remission i. Aplastic anemia (AA)
3. Male or female, age ≥18 years of age
4. Reasonable expectation of survival for at least 3 months, if the transplant procedure is successful
5. Eastern Cooperative Oncology Group (ECOG) status of 0-2 or Karnofsky Performance Status (KPS) of \> 60
6. Transplant Donor
1. Part 1 (Phase 1: Dose Escalation Phase):
Unrelated transplant donor with no more than 1 HLA allele or antigen mismatch, defined as loci A, B, C and DR (note: DQ is excluded)
2. Part 2 (Phase 2a: Expansion Phase):Related or unrelated transplant donor, with no more than 1 HLA allele or antigen mismatch, defined as loci A, B, C and DR (note: DQ is excluded).
7. Source of the allograft
1. Part 1 (Phase 1: Dose Escalation Phase):Unmodified (non-manipulated) bone marrow, or mobilized peripheral blood stem cell (PBSC) transplant, using G-CSF as the mobilizing agent.
2. Part 2: (Phase 2a: Expansion Phase) Unmodified (non-manipulated) bone marrow, or mobilized peripheral blood stem cell (PBSC) transplant, using G-CSF as the mobilizing agent.
8. Anti-graft-versus-host disease (GvHD) prophylaxis:
A calcineurin inhibitor \[either tacrolimus (FK506) or cyclosporin A)\], in combination with either methotrexate (MTX), mycophenolate mofetil (MMF) or sirolimus (RAPA) all at doses as per the institutional protocols
9. Adequate hepatic function, with bilirubin not exceeding the upper limit of normal (except when attributed to Gilbert's Disease), and AST and ALT of less than 1.5 times the upper limit of normal
10. No clinically significant cardiac conduction disorder on screening ECG
11. Serum creatinine ≤ 2.0 mg/dL
12. Female patients of childbearing potential must have a negative serum pregnancy test prior to enrollment and must agree to use dual method of contraception for 30 days after study drug administration. Approved methods of contraception include, an IUD with spermicide, a female condom with spermicide, a diaphragm with spermicide, a cervical cap with spermicide, use of a condom with spermicide by sexual partner or a sterile sexual partner.
13. If male, subjects must be sterile or willing to use an approved method of contraception from the time of Informed Consent to 30 days after study drug treatment. Males must be willing to refrain from sperm donation within 30 days after study drug treatment.
14. No clinically significant acute or chronic medical condition that in the opinion of the investigator will interfere with study participation
15. No clinically significant laboratory abnormalities as determined by the Principal Investigator, in consultation with the Sponsor's Medical Monitor
16. No active infection
17. Have signed written informed consent before undergoing any study related procedures and is willing to comply with all study procedures
Exclusion Criteria
2. Subjects about to undergo a non-ablative or non-myeloablative transplant
3. AML or ALL patient who are in relapse (\>5% blasts) or who are defined as primary refractory
4. Blast crisis CML
5. Radiation, chemotherapy, immunotherapy in the previous 3 weeks, unrelated to the transplant procedure
6. Subjects who, in the judgment of the Investigator have not recovered from the effects of previous therapy
7. Subject who is about to undergo cord blood transplantation
8. Procedures that are intended to deplete regulatory T-cells from donor transplant materials
9. Known or suspected HIV infection
10. Active hepatitis A, B, or C infection in recipient or donor
11. Uncontrolled active infection requiring IV antibiotics in recipient or donor
12. Major surgery within 1 month before Day 0
13. Participation in an investigational study within 1 month prior to Day 0
14. Prior treatment with anti-CD3 antibodies
15. Treatment with anti-CD20 antibodies or anti-thymocyte globulin (ATG) within 3 months of the AHSCT procedure (i.e. infusion of transplant material and RGI-2001).
16. Vaccination within the preceding 2 weeks prior to the planned dose of RGI-2001
17. Planned vaccination within 2 months after study drug administration
18. Known history of cardiac dysfunction (e.g. \<50% ejection fraction), ischemia, conduction abnormalities, or myocardial infarction in the previous six months
19. Cardiac pacemaker or automatic implantable cardioverter-defibrillator
20. Marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval \>450 ms
21. Congenital long QT syndrome or family history of long QT syndrome
22. History of additional risk factors for torsades de pointes (TdP) (e.g., heart failure, hypokalemia)
23. Bundle branch block
24. Connective tissue/rheumatologic disorders
25. History of autoimmune disease
26. History of solid tumor, excluding non-melanoma skin or cervical carcinoma after curative resection, within the preceding 5 years
27. Uncontrolled diabetes
28. Prior allogeneic hematopoietic stem cell transplantation
29. Any other prior organ transplant
30. Psychiatric or addictive disorders that preclude obtaining reliable informed consent
31. Any other condition that, in the opinion of the investigator, renders the subject unsuitable for study participation
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Regimmune Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UCSD Moores Cancer Research Institute
San Diego, California, United States
Stanford School of Medicine
Stanford, California, United States
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States
Ohio State University Comprehensive Cancer Center - The James
Columbus, Ohio, United States
Methodist Healthcare System
San Antonio, Texas, United States
Fred Hutchinson Cancer Research Center
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Regimmune Company Website
Fred Hutchinson Cancer Research Center
Stanford School of Medicine
UCSD Moores Cancer Center
OSU The James Comprehensive Cancer Center
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RGI-2001-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.